This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Azilect, rasagiline, D...
EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, ...
Human medicines European public assessment report (EPAR): Pregabalin Viatris Pha...
Human medicines European public assessment report (EPAR): Refixia, nonacog beta ...
Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sug...
Human medicines European public assessment report (EPAR): Enspryng, satralizumab...
Human medicines European public assessment report (EPAR): Ontozry, cenobamate, D...
Human medicines European public assessment report (EPAR): Qarziba (previously Di...
Human medicines European public assessment report (EPAR): Evrenzo, roxadustat, D...
Human medicines European public assessment report (EPAR): Azacitidine Mylan, aza...
Human medicines European public assessment report (EPAR): Pavblu, aflibercept, S...
Human medicines European public assessment report (EPAR): Lysodren, mitotane, Da...
Agenda of the CVMP meeting 8-10 April 2025
Veterinary medicines safety day: Social media infocards
Veterinary medicines safety day: How to report adverse events - simple guide
Veterinary medicines safety day: Adverse event reporting in the EU - presentation
Guidance on good manufacturing practice and good distribution practice: Question...
Innovation Task Force (ITF) briefing meeting request form
Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab,...
Human medicines European public assessment report (EPAR): Mvabea, Ebola vaccine ...
Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Dat...
Human medicines European public assessment report (EPAR): Fluenz, influenza vacc...
Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tez...